Better Vaccines for a Better World         

Dr. Dan Stinchcomb
Co-founder and CEO

Dr. Stinchcomb co-founded Inviragen with Dr. Osorio in 2005.  Dr. Stinchcomb has over two decades of biotechnology experience including research, product development, approval, and commercialization of vaccines, therapeutics, and diagnostics.  His background includes positions as Executive Vice President of Research and Development at Heska Corporation, Director of Biology at Ribozyme Pharmaceuticals (now Sirna acquired by Merck), and Senior Scientist at Synergen (acquired by Amgen).

Prior to his career in biotechnology, Dr. Stinchcomb was Assistant and Associate Professor at Harvard University. He obtained his Ph.D. at Stanford University and his B.A. at Harvard University. Currently, he serves as an Adjunct Professor of Biochemistry and Molecular Biology at Colorado State University.

Dr. Jorge Osorio
Co-founder and CSO

Dr. Osorio has over 20 years of vaccine research and development experience in academia and industry. Dr. Osorio co-founded Inviragen with Dr. Stinchcomb in 2005 and currently serves as Assistant Professor in the Department of Pathobiological Sciences at the University of Wisconsin.

Prior to founding Inviragen and joining the University of Wisconsin, Dr. Osorio held senior scientific and global project leadership positions at Chiron Vaccines, Powderject, Merial, and Heska Corporation. He has created and demonstrated proof-of-principal for innovative vaccines to protect against influenza, hepatitis B, viral encephalitis, rabies, and plague. He received his Ph.D. from the University of Wisconsin and DVM from Universidad de Antioquia, Colombia.

Dr. Joseph Santangelo
Chief Operating Officer

Joe Santangelo founded SingVax in 2004, merging with Inviragen Inc. in September of 2009.  Prior to taking on the role of COO in the merged company, Dr. Santangelo served as CEO of SingVax and in various R&D roles at Microscience Ltd. from its inception in 1997.  His career in microbiology, infectious disease research, manufacturing and product development spans more than 28 years.

Dr. Santangelo was born, educated and worked in the United States, before moving to South Africa, Germany, the United Kingdom and Singapore.  He has a B.Sc. from the State University of New York, a M.Sc. from the University of Vermont and a Ph.D. from the University of Cape Town.  He was awarded an Alexander von Humboldt fellowship (1993) and is a member of various microbiology and biotechnology societies.

Gilad S. Gordon, MD, MBA
Chief Medical Officer

Dr. Gordon has served as the Chief Medical Officer of Inviragen since 2011. Dr. Gordon has over 23 years experience in the pharmaceutical and biotechnology industry which has encompassed research, product development (Phase I-IV), regulatory affairs, drug approvals, outcomes research, health economics, and marketing of vaccines, drugs, biologicals, devices and diagnostics. Most recently he was President of Orra Group, LLC, a medical consulting firm, was previously Vice President of Medical Affairs at FeRx, and prior to that held various medical management positions at Ribozyme Pharmaceuticals, MediQual, Synergen and Eli Lilly and Company.

Dr. Gordon received his AB, in Biochemistry from Harvard University, and his MD from the Health Sciences and Technology program at Harvard Medical School. Dr. Gordon completed his training in internal medicine at the University of Colorado Health Sciences Center. Subsequently, he was a Senior Fellow in the Robert Wood Johnson Clinical Scholars Program at the University of Washington and concurrently received his MBA. He currently serves as Clinical Associate Professor of Medicine at the University of Colorado Denver where he also has served as an attending physician at the Denver VA Medical Center.

site map | | legal notice